Abstract Objective To investigate the effect of different sequential treatments of Azithromycin on Mycoplasma pneumoniae pneumonia (MPP) in children. Methods A total of 68 children with MPP admitted to Maternity & Child Care Center of Xinyu from September 2020 to September 2022 were selected as the research objects, and they were divided into control group (34 cases) and observation group (34 cases) according to random number table method. Children in both groups were treated with Azithromycin. The control group received intravenous injection of Azithromycin for 3 days, withdrawal for 4 days, and then oral Azithromycin dry suspension for 7 days. Observation group was given intravenous Azithromycin for injection for 5 days, drug withdrawal for 4 days, and then oral Azithromycin dry suspension for 5 days. Both groups were treated for 14 days. The clinical efficacy, duration of clinical symptoms, length of hospital stay, immune function, lung function and adverse reactions were compared between the two groups. Results The total clinical effective rate of the observation group was higher than that of the control group, the difference was statistically significant (P＜0.05). There was no significant difference in the time of fever reduction between the two groups (P＞0.05). The disappearance time of lung rales, cough and hospital stay in observation group were shorter than those in control group, and the differences were statistically significant (P＜0.05). There were no significant differences in immunoglobulin E (IgE), interleukin-3 (IL-3) and eosinophils (EOS) between the two groups before treatment (P＞0.05). The IgE, IL-3 and EOS of the two groups after treatment were lower than those before treatment, and the IgE, IL-3 and EOS of the observation group were lower than those of the control group, with statistical significances (P＜0.05). There were no significant differences in forced expiratory volume in the first second (FEV1), forced vital capacity (FVC) and FEV1/FVC in the first second before treatment between the two groups (P＞0.05). After treatment, FEV1, FVC and FEV1/FVC in the two groups were higher than those before treatment, and FEV1, FVC and FEV1/FVC in the observation group were higher than those in the control group, with statistical significances (P＜0.05). No obvious adverse reactions were observed in the two groups. Conclusion Using Azithromycin for 5 consecutive days under sequential therapy can effectively improve the clinical symptoms and immune function of MPP children, shorten the hospital stay of children, and is safe, worthy of promotion.
JIANG Haihong LIU Pan LIU Lu ZHANG Min AO Xiaodong GUO Zhonghua. Clinical effect of different sequential Azithromycin treatments on Mycoplasma pneumoniae pneumonia in children[J]. 中国当代医药, 2024, 31(1): 55-58,63.
